title: Expression of SIALYL-Le(x) antigen defined by MAb AM-3 is an independent prognostic marker in colorectal carcinoma patients.
abstract: Expression of mucin-bound sialyl-Le(x) antigen during the progression of colorectal carcinoma and its potential prognostic value were analysed in sections of tumours from 182 patients with a documented follow-up by immunohistochemistry using the monoclonal antibody (MAb) AM-3. Two groups of colonic carcinomas with weak (n = 79) and strong (n = 103) sialyl-Le(x) expression were discerned. The percentage of strongly expressing tumours increased with the progression of the disease (UICC stage I = 10%, stage II = 46%, stage III = 63%, stage IV = 68%, p < 0.0001). Seventy-four percent of patients with carcinomas exhibiting a strong sialyl-Le(x) expression but only 34% of patients with weak sialyl-Le(x) expression died of the disease (p = 0.0026). In multivariate analysis, strong sialyl-Le(x) expression increased the relative risk of cancer-related death 3.8-fold (95% CI = 1.8-7.9, p = 0.00034). The separate analyses of patients in UICC stage II (n = 56), III (n =5 9) and IV (n = 57) revealed that strong sialyl-Le(x) expression was associated with a reduction of the 5-year overall survival rate in UICC stage II (84% vs. 54%, p = 0.0013) and in stage III patients (86% vs. 35%, p = 0.0008) after curative resection but was not relevant in patients with distant metastases. In conclusion, the strong expression of sialyl-Le(x) antigen defined by the MAb AM-3 in colorectal carcinomas is an independent unfavourable prognostic factor after curative resection in stage II and III patients. The predictive power of the sialyl-Le(x) expression may be helpful to define subgroups of patients at high risk for whom preventive adjuvant therapy can be selectively applied before the occurrence of detectable metastases.
authors.affiliation: Department of Gastroenterology, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Berlin, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Grabowski
authors.forename: B
authors.initials: B
authors.lastname: Mann
authors.forename: U
authors.initials: U
authors.lastname: Mansmann
authors.forename: N
authors.initials: N
authors.lastname: Lövin
authors.forename: H D
authors.initials: HD
authors.lastname: Foss
authors.forename: G
authors.initials: G
authors.lastname: Berger
authors.forename: H
authors.initials: H
authors.lastname: Scherübl
authors.forename: E O
authors.initials: EO
authors.lastname: Riecken
authors.forename: H J
authors.initials: HJ
authors.lastname: Buhr
authors.forename: C
authors.initials: C
authors.lastname: Hanski
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D007983:Lewis Blood Group Antigens / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009844:Oligosaccharides / Q000032:analysis*; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies; D000080506:Sialyl Lewis X Antigen; D015996:Survival Rate; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D007983:Lewis Blood Group Antigens; D009844:Oligosaccharides; D000080506:Sialyl Lewis X Antigen